Belgian biotech still in European Top-3

Belgium remains a frontrunner in the European biotech landscape. Big companies are doing well, smaller ones have a harder time finding investors. 

With a total market value of 42.1 billion euros, Belgian biotech companies maintain the third position in Europe. Belgium has also managed to narrow the gap with Germany, the number one in Europe. 

The worldwide good renown of the Flemish biotech hub, the availability of highly educated talent in the region and the collaboration between companies, universities and governments, proves to be attractive for investors. 

Last year, the Chinese biotech company Legend, which has its headquarters in the United States, announced a large-scale investment in Zwijnaarde. Legend is now building the production site for CAR-T cell therapy, a cancer therapy, together with Janssen Pharmaceutica. The new site in the Tech Lane science park is expected be ready in 2023. More than hundred employees will be hired.

“We are experiencing an unprecedented wave of scientific insights and new technologies leading to positive clinical developments or new products on the market.”, states Dirk Reyn, chairman of”

Big players like argenx, focussing on autoimmune diseases and cancer, and UCB, focussing on epilepsy, Parkinson's disease, and Crohn's disease, have excellent stock market performances. But companies in earlier stages, although publishing good results or making progress, are less attractive today. Investors allegedly prefer to focus on companies with a proven track record: a late development stage or a large market capitalization, which gives them a higher liquidity. 

“The market environment for life sciences has been very harsh over the past year. Investors preferred safer sectors, making it difficult to attract new capital. Recently we saw more activity again, but the situation remains precarious. We expect investors to remain selective in the public markets.”, says Nathalie Van Den Haute, Head Equity Capital Markets of KBC Securities.



© BELGA PHOTO HADRIEN DURE Prime Minister Alexander De Croo during an event of the federal government and the biopharma industry committed to make Belgium the 'health and biotech valley' of the future

Get updates in your mailbox

By clicking "Subscribe" I confirm I have read and agree to the Privacy Policy.


Belga News Agency delivers dependable, rapid and high-quality information 24 hours a day, 7 days a week, from Belgium and abroad to all Belgian media. The information covers all sectors, from politics, economics and finance to social affairs, sports and culture, not to mention entertainment and lifestyle.

Every day, our journalists and press photographers produce hundreds of photos and news stories, dozens of online information items, plus audio and video bulletins, all in both national languages. Since the end of March 2022 English has been added as a language.

For public institutions, businesses and various organisations that need reliable information, Belga News Agency also offers a comprehensive range of corporate services to meet all their communication needs.


Arduinkaai 29 1000 Brussels